skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

weekly audio catch-up on key global biopharma insights

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 12 November 2021, including: the prospects and plans for Johnson & Johnson’s pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda Pharmaceutical Co. Ltd.; and Moderna, Inc.’s co-founder shares tips on innovation.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(No Way To Go But Grow JJ Outlines Plans To Become A 60bn Pharma In 2025)

(Pharma Will Need To Embrace More Inward-Looking China)

(Takedas Livtencity Approved For Refractory CMV Infection In Transplant Patients)

(Moderna Co-Founder Robert Langers Tips For Innovation)

Read also

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: